ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical
company focused on the development and commercialization of
innovative medicines to address unmet medical needs in central
nervous system (CNS) disorders, today announced the promotion of
Elena Ridloff, CFA to Executive Vice President, Chief Financial
Officer. Ms. Ridloff joined ACADIA Pharmaceuticals in April 2018 as
Senior Vice President, Investor Relations and has served as the
company’s Interim Chief Financial Officer since October 2018.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20190401005246/en/
Elena Ridloff, CFA, Executive Vice
President, Chief Financial Officer (Photo: Business Wire)
“I am really delighted to make this announcement. Elena has
contributed to significant achievements for our business since
joining ACADIA last year. She has played a pivotal role in our
executive management team leading our financial operations while
strengthening our shareholder base and elevating our corporate and
financial communications,” said Steve Davis, ACADIA’s Chief
Executive Officer. “Elena has quickly proved to be a valuable
member, bringing new and different expertise to the team. I look
forward to continuing to work with her at this important and
exciting time in our company’s history.”
“I am honored to take on this new role with ACADIA’s experienced
leadership team and help lead us through our next phase of
financial growth,” said Ms. Ridloff. “We are well positioned to
continue to grow NUPLAZID in Parkinson’s disease psychosis,
leverage pimavanserin in additional indications, and expand our
pipeline through disciplined business development.”
Previously Ms. Ridloff was Senior Vice President, Investor
Relations and Interim Chief Financial Officer at ACADIA
Pharmaceuticals. Prior to joining ACADIA, she was Vice President,
Investor Relations at Alexion Pharmaceuticals and served as a
member of the Operating Committee. Additionally, Ms. Ridloff was
Chief Executive Officer and Managing Member of BIOVISIO, an
independent consulting firm providing strategic, financial and
investor relations counsel to the life sciences industry. She was
also a Managing Director at Maverick Capital, a hedge fund based in
New York, and was responsible for investments in the biotechnology,
pharmaceutical, medical device and life science sectors. Ms.
Ridloff earned her B.A. in History and Sociology of Science from
the University of Pennsylvania. She is also a CFA®
charterholder.
About NUPLAZID® (pimavanserin)NUPLAZID is the first and
only FDA-approved treatment for hallucinations and delusions
associated with Parkinson’s disease psychosis. NUPLAZID is a
non-dopaminergic, selective serotonin inverse agonist (SSIA)
preferentially targeting 5-HT2A receptors that are thought to
play an important role in Parkinson’s disease psychosis. NUPLAZID
is an oral medicine taken once a day with a recommended dose of 34
mg. ACADIA discovered and developed this new chemical entity and
holds worldwide rights to develop and commercialize NUPLAZID.
About ACADIA PharmaceuticalsACADIA is a biopharmaceutical
company focused on the development and commercialization of
innovative medicines to address unmet medical needs in central
nervous system disorders. ACADIA has developed and is
commercializing the first and only medicine approved for the
treatment of hallucinations and delusions associated with
Parkinson’s disease psychosis. In addition, ACADIA has ongoing
clinical development efforts in additional areas with significant
unmet need, including dementia-related psychosis, schizophrenia
inadequate response, schizophrenia-negative symptoms, major
depressive disorder, and Rett syndrome. This press release and
further information about ACADIA can be found at:
www.acadia-pharm.com.
Forward-Looking StatementsStatements in this press release that
are not strictly historical in nature are forward-looking
statements. These statements include, but are not limited to,
statements related to the potential opportunity for future growth
in sales of NUPLAZID. These statements are only predictions based
on current information and expectations and involve a number of
risks and uncertainties. Actual events or results may differ
materially from those projected in any of such statements due to
various factors, including the uncertainty of future commercial
sales and related items that would impact net sales during 2019,
the risks and uncertainties inherent in drug discovery,
development, approval and commercialization, and the fact that past
results of clinical trials may not be indicative of future trial
results. For a discussion of these and other factors, please refer
to ACADIA’s annual report on Form 10-K for the year ended December
31, 2018 as well as ACADIA’s subsequent filings with the Securities
and Exchange Commission. You are cautioned not to place undue
reliance on these forward-looking statements, which speak only as
of the date hereof. This caution is made under the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995.
All forward-looking statements are qualified in their entirety by
this cautionary statement and ACADIA undertakes no obligation to
revise or update this press release to reflect events or
circumstances after the date hereof, except as required by law.
Important Safety Information and
Indication for NUPLAZID (pimavanserin)
WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH
DEMENTIA-RELATED PSYCHOSIS
- Elderly patients with
dementia-related psychosis treated with antipsychotic drugs are at
an increased risk of death.
- NUPLAZID is not approved for the
treatment of patients with dementia-related psychosis unrelated to
the hallucinations and delusions associated with Parkinson’s
disease psychosis.
Contraindication: NUPLAZID is contraindicated in patients
with a history of a hypersensitivity reaction to pimavanserin or
any of its components. Rash, urticaria, and reactions consistent
with angioedema (e.g., tongue swelling, circumoral edema, throat
tightness, and dyspnea) have been reported.
QT Interval Prolongation: NUPLAZID prolongs the QT
interval. The use of NUPLAZID should be avoided in patients with
known QT prolongation or in combination with other drugs known to
prolong QT interval including Class 1A antiarrhythmics or Class 3
antiarrhythmics, certain antipsychotic medications, and certain
antibiotics. NUPLAZID should also be avoided in patients with a
history of cardiac arrhythmias, as well as other circumstances that
may increase the risk of the occurrence of torsade de pointes
and/or sudden death, including symptomatic bradycardia, hypokalemia
or hypomagnesemia, and presence of congenital prolongation of the
QT interval.
Adverse Reactions: The most common adverse reactions (≥2%
for NUPLAZID and greater than placebo) were peripheral edema (7% vs
2%), nausea (7% vs 4%), confusional state (6% vs 3%), hallucination
(5% vs 3%), constipation (4% vs 3%), and gait disturbance (2% vs
<1%).
Drug Interactions: Coadministration with strong CYP3A4
inhibitors (e.g., ketoconazole) increases NUPLAZID exposure. Reduce
NUPLAZID dose to 10 mg taken orally as one tablet once daily.
Coadministration with strong CYP3A4 inducers may reduce NUPLAZID
exposure. Monitor patients for reduced efficacy and an increase in
NUPLAZID dosage may be needed.
Pediatric Use: Safety and efficacy have not been
established in pediatric patients.
Dosage and Administration: Recommended dose: 34 mg taken
orally once daily, without titration.
Indication: NUPLAZID is an atypical antipsychotic
indicated for the treatment of hallucinations and delusions
associated with Parkinson’s disease psychosis.
You are encouraged to report negative side effects of
prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call
1-800-FDA-1088. You can also call ACADIA Pharmaceuticals Inc. at
1-844-4ACADIA (1-844-422-2342).
NUPLAZID is available as 34 mg capsules and 10 mg tablets.
Please see the full Prescribing Information including Boxed
WARNING for NUPLAZID at
https://www.nuplazid.com/pdf/NUPLAZID_Prescribing_Information.pdf.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190401005246/en/
Investor Contact:ACADIA Pharmaceuticals Inc.Mark Johnson,
CFA(858) 261-2771ir@acadia-pharm.com
Media Contact:ACADIA Pharmaceuticals Inc.Maurissa Messier(858)
768-6068media@acadia-pharm.com
Acadia Pharmaceuticals (NASDAQ:ACAD)
Historical Stock Chart
From Mar 2024 to Apr 2024
Acadia Pharmaceuticals (NASDAQ:ACAD)
Historical Stock Chart
From Apr 2023 to Apr 2024